2023-508349-42-00
CTIS ↗
FURMO-002
Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations
biotech · Metastatic Non-Small Cell Lung Cancer · NSCLC · AVBP
ArriVent BioPharma
ArriVent BioPharma trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Newtown Square, USA HQ
75 Employees
Public company Type
AVBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Newtown Square, USA
- Employees
- 75
- Programs
- 7
- Drugs
- 4
- Patents
- 0
ArriVent BioPharma clinical trials
Registry index of 7 ClinicalTrials.gov studies linked to ArriVent BioPharma programs — each row shows trial ID, program name, phase, status, and indication.
ArriVent BioPharma trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for ArriVent BioPharma.